

Biomarker Analysis in Tissue-based Assays

Image Analysis for Life Sciences and Medicine

Dr. Maria Athelogou Senior Research Scientist



Company History



1995: Delphi Systemsimulation GmbH

founded by Physics Nobel Prize Laureate Prof. Dr. Gerd Binnig funded by Deutsche Bundesstiftung Umwelt focus on simulation of complex ecologies and economies

1998: Cognition Network Technology (CNT)

solves problem of knowledge extraction from unstructured data

20+ patents

2000: Definiens AG, Commercialization

funded by TVM (today also by CIPIO Partners)

2003: Focus on **Enterprise Image Intelligence**

2008: Staff 83, **1500+** licenses worldwide,

HQ Munich, US operations, Definiens Inc.





Company Background




- Ground breaking Cognition Network Technology
- Focus on Digital Images
- Target Life Sciences and Earth Sciences markets
- Direct operations in Europe and North America
- Focus on Health Imaging as prime market



The Explosion of Digital Image Content





Images per Device

DEF: **NIENS**° Understanding Images


Image Analysis Represents a Major Bottleneck



Complexity

Human Mind





NOT SOLVED!

→Productivity

Computer Based Methods





Image Analysis Represents a Major Bottleneck



Human Mind




Intelligent handling of complex tasks, but the required manual quantification is

- •expensive
- •subjective
- very time consuming

Conventional image analysis techniques

Only very simple tasks can be addressed

Definiens Technology




Complex tasks can be addressed automatically, quantification is

- inexpensive
- •reproducible
- •fast



Cognition Network Technology, CNT






The Definiens' Cognition Network Technology, CNT, enables automated context-driven analysis by emulating the human cognition process




Cognition Network Language is a meta language for Image Understanding

- Definiens image analysis software supports a GUI based meta language that allows for fast and efficient development of rule bases.
- □ A rule base addresses the solution of a specific image analysis task
- Basic components are processes and fuzzy classification that support knowledge based segmentation



Classes with fuzzy class descriptions



Cognition Network Technology, CNT



Three major markets are addressed by Definiens

- Life Sciences (Bio-Tech and pharmaceutical industries)
- •Medical imaging (CT, MRI,..)
- Earth Sciences (satellite, air-born images)

Earth Sciences market is not addressed in this presentation



Life Sciences Customers (samples)




























































Slide - 10 Confidential



Cross-Modality – Cross-Manufacturer – Cross-Domain



All Stages

Discovery, Pre-clinical, Clinical, Diagnostics

All Dimensions

2D, 3D, 4D, xD

All Modalities

Microscope, Scanner, MRI, CT, Mammography

All Therapeutic Areas

Oncology, Neurology, Cardiology, Urology, Inflammation & Infectious Diseases, Immunology, Respiratory, etc.

All Objects

Cell, Tissues, Organ, Body

All Methods

In-vivo, In-vitro

All Models


Human, Animal



Traveling through the Dimensions of Space



Real Space / Size of Objects







One Technology – Many Applications

Automatic Detection of Image Contents







Electron Microscopy **Tissue**




High Content Sreening Cells




Proliferation index Tissue




Cancer Biomarker Tissue



3D-Confocal Microscopy Cell biology



3D-Confocal Microscopy **Tissue** Molecular Pathology



3D PET/CT
Small animal




Example: Preclinical Safety for Drug Development



Analysis of proliferation index in mouse jejunum

Input Data Cellenger Result






Image data courtesy Novartis Pharma AG; Pathology / Toxicology EU, E. Persohn



Variability





Image data courtesy Novartis Pharma AG; Pathology / Toxicology EU; E. Persohn

DEF:NIENS Understanding Images


Benefit of Definiens Technology



- Request from the FDA / EMEA) → additional Tox./ Histopath. Data for the final submission
- Stack of approx. 15.000 images
- Based on state of the art technologies
- Expected 3 -4 Pathologists → 6 months
- Automated, quantitative Analysis of cell & tissues
- Benchmark (Pathologist / eCognition)
- Result within a few weeks
- Reduced the time from 6 to 1 months with 2 Pathologists
- Time to market benefit








Biopsy Breast Cancer, Biomarker Ki-67 Single cell based solution






Biopsy Breast Cancer, Biomarker Her2/neu Single cell based solution




Original 0 : her2Neu_File174

Original 2 : her2Neu_File177



Original 3 : her2Neu_File179




Slide - 19 Confidential




Analysis Results



Original 0 : her2Neu_174



Original 3 : her2Neu_179



Slide - 20

Confidential


DEF: **NIENS**° Understanding Images

Statistics




Count of cells of different classes

Original 0 : her2Neu_174




Original 2 : her2Neu_177



Confidential

Original 3 : her2Neu_179







Slide - 21

3D Tissue: optical slices Biopsy Breast Cancer, Biomarker FISH Her2/neu














Definiens Tissue Map*

Automated Image Analysis for the Advanced Development of Predictive Biomarkers and Companion Diagnostics



Is a powerful platform for developing multidimensional image analysis applications for cells, tissues and organs.

Has been developed specifically for oncology research and comes with a dedicated suite of algorithms.

automates the challenging task of image analysis,


supporting research scientists to discover, validate and measure new drug targets and disease-specific biomarkers.

It helps to monitor preclinical efficacy and safety, to stratify patients for clinical trials and supports personalized medicine.

DEF: NIENS Understanding Images

Tissue Slides






Analysis of antibodies and markers which co-stain the cell body, like cytokeratine markers (CD31, AE1/3, etc.) and other markers, such as CD45, CD23, etc.




Slide - 26 Confidential


TMAs






Assigned TMA-cores to layout. Upper left section: original TMAslide with automatically detected cores (green circles) and selection (red rectangles). Lower section left: cores assigned to grid. Lower right section: core detection and matching control functions.








The HeatMap Visualization tool enables the comparison of statistical data in experimental samples.





Fully automated detection of xenograft and separation of viable and necrotic regions of the tumor.








Definiens TissueMap: enables research scientists to examine whole tissue section slides and tissue micro arrays in many different ways. It can:

- Manually select and quantify complex regions of interest in whole section slides
- Analyze xenografts including the detection of viable and necrotic regions
- Automatically detect and match cores in TMAs
- Analyze nuclear markers: detection of proliferation marker, e.g. Ki67/MIB1, PCNA, BrdU, steroid, hormone receptor marker like estrogen (ER), progesterone (PR) and apoptosis marker
- Analyze cytoplasmic markers: detection of regions of IHC stained cells using cytoceratin stains like AE1/3, CK5, CK15, CK8, CK14.
- Analyze membrane markers: detection and quantification of amount and intensity of stains in membranes, e.g. detection of membrane resident hormone-receptors like Her2neu or EFGR
- Classify positive nuclei based on intensity of IHC stain
- Customize and extend the Action Library with new image analysis routines
- Use clearly defined and documented interfaces between analysis steps
- Calculate fractions/ratios, areas, number and relationships
- Export statistics per slide or per TMA core respectively



Traveling through the Dimensions of Space







One Technology – Many Applications

Automatic Detection of Image Contents







Biopsy Tissue




CT Liver tumor




Serum Cells




CT Blood vessels




X-Ray Mammography



MRI Ventricles



CT Head/Neck





CT Lymph Nodes



Lymph Node Evaluation across the diagnostic and therapeutic chain








Assessment of metastasis by evaluation of lymphatic system

Staging



Assessment of therapy response by measuring lymph nodes



Breast Cancer Prostate Cancer Colon Cancer Lung Cancer













Therapy














Tomorrow: 3D-View and 3D-Quantification









Definiens Lymph Node Applications












Target Markets

- Semi-Automatic: Pharma and CRO companies to support clinical phase trials
- <u>Fully-Automatic:</u> Radiological institutes of all sizes; equipment manufacturers and SW companies as OEM partners



One Technology – Many Applications

Traveling through the Dimensions of Space



Automatic Detection of Image Contents



Thank You for Your Attention



Further information is available on

www.definiens.com

DKloos@definiens.com Senior Account Manager Life Sciences

mathelogou@definiens.com Senior Research Scientist

Please also visit the DEFINIENS booth

Dr. G. Zehner, Field Application specialist

Corporate Headquarters:

Trappentreustraße 1

80339 Munich

Germany

Tel. +49-(0)89-231180-0

Fax +49-(0)89-231180-90

Americas Headquarters:

55 Madison Avenue, Suite 400

Morristown, NJ 07960

Tel. +1-973-285-3291

Fax +1-973-285-3292

